Please login to the form below
Emma Walmsley
This page shows the latest Emma Walmsley news and features for those working in and with pharma, biotech and healthcare.
GSK appoint Tony Wood as chief scientific officer
CEO of GSK, Emma Walmsley said: “We are delighted to appoint Tony as our next CSO. ... Walmsley added that the recent changes to GSK’s senior leadership provide “a clear pathway for continued momentum in R&D to deliver our new ambitions for growth
Latest news
-
GSK/Merck KGgA cancer drug fails in third trial
Earlier this summer, GSK CEO Emma Walmsley took time to reassure investors that the company’s new approach was bearing fruit.
-
GSK beats expectations thanks to strong vaccine sales in Q2
range for 2021, and meaningful performance improvement in 2022,” said Emma Walmsley, chief executive officer of GSK. ... In response, GSK’s board said that it ‘strongly believes’ that Walmsley is the ‘right leader’ for the new biopharma
-
GSK reveals plans for £400m R&D facility expansion in England
Last month, GSK unveiled its ten-year strategy, with chief executive officer Emma Walmsley revealing the company is expecting product sales to reach £33bn ($46bn) by 2031. ... Walmsley has come under increasing pressure to improve GSK’s performance
-
GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business. ... In response to a 17-page letter from activist hedge fund Elliott Management last week, GlaxoSmithKline (GSK) has thrown its support
-
Elliott Management puts pressure on GSK after years of ‘disappointing performance’
Although GSK’s chief executive officer Emma Walmsley was not named, Elliott highlighted ‘leadership failures’ regarding the company’s plans for the consumer health/biopharma separation.
More from news
Approximately 2 fully matching, plus 58 partially matching documents found.
Latest Intelligence
-
Women Leaders in UK Healthcare: Liz Henderson
It’s also great to see outside Merck that women are also progressing in other companies too – like Emma Walmsley at GSK – which gives women the inspiration that they too can
-
25 Women Leaders in UK Healthcare
10. THEODORA HAROLD . Biotech leader. While big pharma is making some significant strides in having women as their top leaders (most notably GSK’s CEO Emma Walmsley), the biotech sector, particularly
-
Diversity and inclusion in the pharma industry
If, as GlaxoSmithKline CEO Emma Walmsley said, talking about diversity to Business Insider UK, ‘‘You cannot be a modern employer in an industry that should be future facing and modernising arguably
-
30 Women Leaders in UK Healthcare (part 3)
29. Emma Walmsley, GSK CEO. Emma Walmsley is the first-ever woman leader of a big pharma company, having taken on the CEO role at GlaxoSmithKline in April 2017. ... Since then, Walmsley has very definitely put her own stamp on the firm, making major
-
Pharma deals continue to slide
Emma Walmsley, CEO of GSK, said: “We will use cash for business development purposes, with M&A obviously dependent on the right kind of return profile.”.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
GSK appoints president of global pharmaceuticals
Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Wave Healthcare Communications
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
